AXIM Biotechnologies, Inc. (AXIM) stock
AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
AXIM Biotechnologies profit margin
Profit margin (net margin) is net income as a percentage of revenue.
AXIM Biotechnologies's profit margin for the twelve months ending Jun 30, 2024 was -4452.1%. For fiscal 2023 it was -20395.0%, against -70343.1% the year before. The highest annual figure on record is -27.9% in fiscal 2011.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -20395.0% | +49948.1 |
| FY2022 | Dec 31, 2022 | -70343.1% | −43825.9 |
| FY2021 | Dec 31, 2021 | -26517.2% | −25710.7 |
| FY2019 | Dec 31, 2019 | -806.5% | +2646.6 |
| FY2018 | Dec 31, 2018 | -3453.0% | +5308.7 |
| FY2017 | Dec 31, 2017 | -8761.7% | +3584.3 |
| FY2016 | Dec 31, 2016 | -12346.0% | +8193.2 |
| FY2015 | Dec 31, 2015 | -20539.2% | −20127.4 |
| FY2013 | Dec 31, 2013 | -411.8% | −377.4 |
| FY2012 | Dec 31, 2012 | -34.4% | −6.5 |
| FY2011 | Dec 31, 2011 | -27.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2024 | Jun 30, 2024 | -12986.0% | +24513.2 |
| Q1 FY2024 | Mar 31, 2024 | -551.7% | +36796.2 |
| Q4 FY2023 | Dec 31, 2023 | -14793.0% | −2902.4 |
| Q3 FY2023 | Sep 30, 2023 | 3428.3% | +158264.5 |
| Q2 FY2023 | Jun 30, 2023 | -37499.2% | +129878.0 |
| Q1 FY2023 | Mar 31, 2023 | -37348.0% | +3155.0 |
| Q4 FY2022 | Dec 31, 2022 | -11890.6% | +13836.6 |
| Q3 FY2022 | Sep 30, 2022 | -154836.1% | −152188.2 |
| Q4 FY2021 | Dec 31, 2021 | -167377.2% | −167197.6 |
| Q3 FY2021 | Sep 30, 2021 | -40503.0% | −26771.8 |
| Q2 FY2021 | Jun 30, 2021 | -25727.2% | −25140.9 |
| Q1 FY2021 | Mar 31, 2021 | -2648.0% | +18780.3 |
| Q4 FY2019 | Dec 31, 2019 | -179.6% | +20355.8 |
| Q1 FY2019 | Mar 31, 2019 | -13731.2% | +5664.5 |
| Q4 FY2018 | Dec 31, 2018 | -586.3% | +8714.5 |
| Q3 FY2018 | Sep 30, 2018 | -21428.3% | −4604.1 |
| Q2 FY2018 | Jun 30, 2018 | -20535.4% | −5427.4 |
| Q1 FY2018 | Mar 31, 2018 | -19395.6% | −16580.6 |
| Q4 FY2017 | Dec 31, 2017 | -9300.7% | +390.5 |
| Q3 FY2017 | Sep 30, 2017 | -16824.2% | +1755.4 |
| Q2 FY2017 | Jun 30, 2017 | -15108.0% | +1692.7 |
| Q1 FY2017 | Mar 31, 2017 | -2815.0% | +3997.5 |
| Q4 FY2016 | Dec 31, 2016 | -9691.2% | +31311.9 |
| Q3 FY2016 | Sep 30, 2016 | -18579.6% | −10695.8 |
| Q2 FY2016 | Jun 30, 2016 | -16800.7% | −3915.3 |
| Q1 FY2016 | Mar 31, 2016 | -6812.6% | – |
| Q4 FY2015 | Dec 31, 2015 | -41003.1% | – |
| Q3 FY2015 | Sep 30, 2015 | -7883.8% | – |
| Q2 FY2015 | Jun 30, 2015 | -12885.5% | – |
See a number that looks wrong?